Financial Performance - Revenue for the six months ended June 30, 2024, was approximately RMB 6,635,688,000, a decrease of about 3.8% compared to RMB 6,897,700,000 in the same period of 2023[2] - Net profit attributable to the owners of the company for the same period was approximately RMB 1,107,549,000, down 7.5% from RMB 1,197,767,000 in 2023[2] - Gross profit for the six months was RMB 3,376,443,000, down from RMB 3,543,479,000 in 2023, reflecting a decrease in gross margin[4] - For the six months ended June 30, 2024, the company reported a net profit of RMB 1,107,549,000, a decrease of 7.5% compared to RMB 1,197,767,000 for the same period in 2023[15] - Total revenue for the six months ended June 30, 2024, was RMB 6,635,688,000, down from RMB 6,897,700,000 in the same period of 2023, representing a decline of approximately 3.8%[24][26] - The company's pre-tax profit reached RMB 1,107,549,000 for the six months ending June 30, 2024, compared to RMB 1,197,767,000 in the same period of 2023, reflecting a decrease of approximately 7.5%[37] Dividends - The board proposed an interim dividend of RMB 0.0919 per share, compared to RMB 0.0734 per share in the same period last year[2] - The company confirmed a dividend distribution of RMB 425,093,000 for the six months ended June 30, 2024, compared to RMB 356,122,000 in the previous year, marking an increase of 19.4%[15] - The interim dividend payment rights will be determined from October 22, 2024, to October 25, 2024, during which H-share transfer registration will be suspended[92] - The deadline for submitting transfer documents for the interim dividend is October 21, 2024, at 4:30 PM[93] - The interim dividend will be distributed on November 22, 2024, or before, to eligible shareholders at their registered addresses[93] Assets and Liabilities - Total assets as of June 30, 2024, were RMB 19,540,925,000, an increase from RMB 18,634,291,000 at the end of 2023[9] - The company’s total equity attributable to owners increased to RMB 23,075,789,000 from RMB 22,449,121,000 at the end of 2023[10] - The company’s non-current assets increased to RMB 15,001,564,000 from RMB 15,035,940,000 at the end of 2023, indicating stability in long-term investments[9] - The company’s total assets as of June 30, 2024, were RMB 10,262,082,000, compared to RMB 9,949,993,000 as of December 31, 2023, indicating an increase of approximately 3.1%[41] - The total liabilities increased from RMB 4,546,147,000 to RMB 5,024,718,000, with current liabilities rising from RMB 4,319,784,000 to RMB 4,741,221,000[52] Research and Development - Research and development expenses increased to RMB 301,613,000 from RMB 294,558,000 in the previous year, indicating a focus on innovation[4] - Research and development expenses for the six months ended June 30, 2024, were approximately RMB 301,613,000, accounting for 4.5% of total revenue[63] - The company continues to focus on research and development in medical devices, orthopedic products, and blood management products, aiming for market expansion and technological advancements[17][22] Operational Highlights - The external sales breakdown for the six months ended June 30, 2024, included RMB 3,292,636,000 from medical devices, RMB 744,991,000 from orthopedic products, and RMB 1,167,605,000 from pharmaceutical packaging[24] - The company added 112 new hospital clients, 29 other medical institutions, and 129 distributors in the domestic market during the reporting period[65] - The company is actively expanding production capacity and improving production processes to meet future market growth demands[64] - The company is focusing on internationalization, digitalization, and platformization as part of its strategic initiatives to adapt to market changes and enhance competitiveness[86] Cost Management - The total cost of goods sold was RMB 3,259,245,000, a decrease from RMB 3,354,221,000 in the previous year, representing a decline of about 2.8%[30] - The group actively reduced production costs to offset the impact of price reductions on gross profit margin[59] Shareholder Information - A total of 94,260,000 shares have been issued under the incentive share plan, with 129,558,616 shares remaining available for issuance, representing approximately 2.83% of the total issued share capital[96] - The maximum number of shares that can be granted to eligible participants under the incentive share plan is capped at 0.5% of the issued share capital on the grant date[96] - As of June 30, 2024, a total of 1,110,000 shares from the first batch of share rewards are exercisable, along with 14,456,000 shares held by the trustee for the benefit of the incentive share plan[99] Corporate Governance - The company has complied with all corporate governance codes as of June 30, 2024, ensuring high standards of governance[7] - The audit committee, consisting of four independent non-executive directors, has reviewed the unaudited consolidated financial statements for the six months ending June 30, 2024[9] - The company is committed to maintaining high standards of corporate governance for long-term success and sustainable development[7] - The board of directors includes a diverse group of members, ensuring a range of perspectives in decision-making[15]
威高股份(01066) - 2024 - 中期业绩